Although cancer cells tend to overexpress CD47, most normal cells, including hematopoietic cells, endothelial and epithelial cells, and fibroblasts (Human Protein Atlas) [62], express CD47 as well, which may have resulted in the observed toxicity of magrolimab therapy. This evidence concerns the gene CD47 and cancer.